- Controversy arises over illegal rebates made by Company A
- by Nho, Byung Chul | translator Kim, Jung-Ju | Oct 17, 2023 05:28am
A multinational pharmaceutical company only seeks to expand its sales
Expediently used corporate credit cards under implicit approval from the CEO
Made illegal cash-back transactions using credit cards and provided expensive groceries to prescribing doctors
The same company that had received administrative action and sales suspension dispositions for the same issue 10 years ago
The multinational pharmaceutical company A's illegal rebate activities have gone too far and are disrupting competition in relevant markets.
According to an anonymous tip on the 15th, Company A has been providing economic benefits to prescribers at large general hospitals to promote drug sales.
The same company was investigated by the Fair Trade Commission and the police around 10 years ago, and the Ministry of Food and Drug Safety imposed a fine for related products at the time.
Company A owns several global blockbuster products, and although relatively inexpensive latecomer generics have been released for many of their blockbusters, the company’s performance improved by 20% over the past 3 years.
Com
-
- 0
If you want to see the full article, please JOIN US (click)
- [Reporter’s View] Consideration in legislating telemedicine
- Reporter's view | Lee, Jeong-Hwan
-
- "High hopes for reimbursed Ilaris…a new treatment option"
- Dr. Soyoung Lee, Professor of Pediatric & Adolescent Medicine at Hallym University Sacred Heart Hospital
-
- Approval called for drug switching in atopic dermatitis
- Dr. Yang Won Lee, Professor in the Department of Dermatology at Konkuk University Medical Center
-
- "Reimb granted to drug switching between JAK inhibitors"
- Dr. Seung-Jae Hong, Professor in the Department of Rheumatology at Kyung Hee University Medical Center
MOST READ
